These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34475526)

  • 1. Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer.
    Nguyen HG; Lundström O; Blank A; Dawson H; Lugli A; Anisimova M; Zlobec I
    Mod Pathol; 2022 Feb; 35(2):240-248. PubMed ID: 34475526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.
    Walsh MD; Clendenning M; Williamson E; Pearson SA; Walters RJ; Nagler B; Packenas D; Win AK; Hopper JL; Jenkins MA; Haydon AM; Rosty C; English DR; Giles GG; McGuckin MA; Young JP; Buchanan DD
    Mod Pathol; 2013 Dec; 26(12):1642-56. PubMed ID: 23807779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
    Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
    World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
    Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
    Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma.
    Imai Y; Yamagishi H; Fukuda K; Ono Y; Inoue T; Ueda Y
    World J Gastroenterol; 2013 Jul; 19(25):3957-68. PubMed ID: 23840140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
    Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
    Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients.
    van de Weerd S; Smit MA; Roelands J; Mesker WE; Bedognetti D; Kuppen PJK; Putter H; Tollenaar RAEM; Roodhart JML; Hendrickx W; Medema JP; van Krieken JHJM
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathological classification of colorectal cancer.
    Müller MF; Ibrahim AE; Arends MJ
    Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.
    Chida K; Kawazoe A; Suzuki T; Kawazu M; Ueno T; Takenouchi K; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Kuwata T; Sakamoto N; Watanabe J; Mano H; Ikeda M; Shitara K; Endo I; Nakatsura T; Yoshino T
    Clin Cancer Res; 2022 May; 28(10):2110-2117. PubMed ID: 35254400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of the chromosome 11 mucin genes in colorectal cancer.
    Sylvester PA; Myerscough N; Warren BF; Carlstedt I; Corfield AP; Durdey P; Thomas MG
    J Pathol; 2001 Oct; 195(3):327-35. PubMed ID: 11673830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of sessile serrated adenoma/polyps with dysplasia/carcinoma based on immunohistochemistry, next-generation sequencing, and microsatellite instability testing: a case series study.
    Murakami T; Akazawa Y; Yatagai N; Hiromoto T; Sasahara N; Saito T; Sakamoto N; Nagahara A; Yao T
    Diagn Pathol; 2018 Nov; 13(1):88. PubMed ID: 30458818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature.
    Kesari MV; Gaopande VL; Joshi AR; Babanagare SV; Gogate BP; Khadilkar AV
    Indian J Gastroenterol; 2015 Jan; 34(1):63-7. PubMed ID: 25731647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.